Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of <10 ng/ml undergoing radical prostatectomy for prostate cancer?

被引：20
|
作者：
Burkhard, FC [1 ]
Schumacher, M [1 ]
Thalmann, GN [1 ]
Studer, UE [1 ]
机构：
[1] Univ Bern, Dept Urol, Bern, Switzerland
来源：
BJU INTERNATIONAL | 2005年 / 95卷 / 03期
关键词：
D O I：
10.1111/j.1464-410X.2005.05280.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 278
页数：4
相关论文
共 50 条
  • [1] Is pelvic lymph node dissection necessary in patients with a serum PSA < 10 ng/ml undergoing radical prostatectomy for prostate cancer?
    Schumacher, Martin C.
    Burkhard, Fiona C.
    Thalmann, George N.
    Fleischmann, Achim
    Studer, Urs E.
    [J]. EUROPEAN UROLOGY, 2006, 50 (02) : 272 - 279
  • [2] Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml
    Ou, YC
    Chen, JT
    Cheng, CL
    Ho, HC
    Yang, CR
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (11) : 574 - 579
  • [3] The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml
    C Bastide
    R Kuefer
    M Loeffler
    R de Petriconi
    J Gschwend
    R Hautmann
    [J]. Prostate Cancer and Prostatic Diseases, 2006, 9 : 239 - 244
  • [4] The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml
    Bastide, C.
    Kuefer, R.
    Loeffler, M.
    de Petriconi, R.
    Gschwend, J.
    Hautmann, R.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (03) : 239 - 244
  • [5] Adverse Pathological Outcomes in Radical Prostatectomy Specimens in Patients with a Serum Prostate-specific Antigen Level ≤3 ng/mL
    Karsiyakali, Nejdet
    Oezgen, Mahir Buelent
    Oezveren, Bora
    Durak, Haydar
    Dincer, Alp
    Tuerkeri, Levent
    [J]. UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2023, 22 (04): : 138 - 143
  • [6] The role of radical prostatectomy in patients with pretreatment prostate-specific antigen ≥40 ng/mL
    Vanasupa, BP
    Paquette, EL
    Wu, HY
    Sun, L
    McLeod, DG
    Moul, JW
    [J]. UROLOGIC ONCOLOGY, 2002, 7 (04): : 167 - 172
  • [7] Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy
    Mandel, Philipp
    Hoeh, Benedikt
    Preisser, Felix
    Wenzel, Mike
    Humke, Clara
    Welte, Maria-Noemi
    Jerrentrup, Inga
    Koellermann, Jens
    Wild, Peter
    Tilki, Derya
    Haese, Alexander
    Becker, Andreas
    Roos, Frederik C.
    Chun, Felix K. H.
    Kluth, Luis A.
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL
    Yamamoto, S
    Ito, T
    Akiyama, A
    Aizawa, T
    Miki, M
    Tachibana, M
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2001, 8 (07) : 374 - 379
  • [9] Comparison among different precursor prostate-specific antigen isoform derivatives on prostate cancer prediction in patients with serum prostate-specific antigen bellow 10 ng/ml
    Stojadinovic, Milorad M.
    Pantic, Damnjan N.
    Andjelkovic, Marija, V
    Stojadinovic, Miroslav M.
    [J]. SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2020, 148 (3-4) : 160 - 166
  • [10] The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml
    Akdas, A
    Tarcan, T
    Turkeri, L
    Cevik, I
    Biren, T
    Ilker, Y
    [J]. EUROPEAN UROLOGY, 1996, 29 (02) : 189 - 192
12345